Lilly signs up to cancer vaccines with CureVac deal
Eli Lilly has signed up CureVac to develop cancer vaccines based on its mRNA technology, in a deal that could potentially be worth more than $2.6 billion to the German biotech.
Read More
Tag: neoantigens
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
